283 related articles for article (PubMed ID: 34216856)
21. A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.
Perez-Lorenzo R; Gill KZ; Shen CH; Zhao FX; Zheng B; Schulze HJ; Silvers DN; Brunner G; Horst BA
J Invest Dermatol; 2014 May; 134(5):1359-1368. PubMed ID: 24288008
[TBL] [Abstract][Full Text] [Related]
22. INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.
Chen H; Li H; Chen Q
Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):700-708. PubMed ID: 28261855
[TBL] [Abstract][Full Text] [Related]
23. INPP4B is an oncogenic regulator in human colon cancer.
Guo ST; Chi MN; Yang RH; Guo XY; Zan LK; Wang CY; Xi YF; Jin L; Croft A; Tseng HY; Yan XG; Farrelly M; Wang FH; Lai F; Wang JF; Li YP; Ackland S; Scott R; Agoulnik IU; Hondermarck H; Thorne RF; Liu T; Zhang XD; Jiang CC
Oncogene; 2016 Jun; 35(23):3049-61. PubMed ID: 26411369
[TBL] [Abstract][Full Text] [Related]
24. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
Ye Y; Jin L; Wilmott JS; Hu WL; Yosufi B; Thorne RF; Liu T; Rizos H; Yan XG; Dong L; Tay KH; Tseng HY; Guo ST; de Bock CE; Jiang CC; Wang CY; Wu M; Zhang LJ; Hersey P; Scolyer RA; Zhang XD
Nat Commun; 2013; 4():1508. PubMed ID: 23443536
[TBL] [Abstract][Full Text] [Related]
25. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
26. INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.
Vo TT; Fruman DA
Cancer Discov; 2015 Jul; 5(7):697-700. PubMed ID: 26152921
[TBL] [Abstract][Full Text] [Related]
27. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
28. Phosphoinositide 3-kinase and INPP4B in human breast cancer.
Bertucci MC; Mitchell CA
Ann N Y Acad Sci; 2013 Mar; 1280():1-5. PubMed ID: 23551093
[TBL] [Abstract][Full Text] [Related]
29. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
30. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles.
Déléris P; Bacqueville D; Gayral S; Carrez L; Salles JP; Perret B; Breton-Douillon M
J Biol Chem; 2003 Oct; 278(40):38884-91. PubMed ID: 12847108
[TBL] [Abstract][Full Text] [Related]
31. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.
Ooms LM; Horan KA; Rahman P; Seaton G; Gurung R; Kethesparan DS; Mitchell CA
Biochem J; 2009 Apr; 419(1):29-49. PubMed ID: 19272022
[TBL] [Abstract][Full Text] [Related]
32. 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Taylor V; Wong M; Brandts C; Reilly L; Dean NM; Cowsert LM; Moodie S; Stokoe D
Mol Cell Biol; 2000 Sep; 20(18):6860-71. PubMed ID: 10958682
[TBL] [Abstract][Full Text] [Related]
33. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
34. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Ramaswamy S; Nakamura N; Vazquez F; Batt DB; Perera S; Roberts TM; Sellers WR
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2110-5. PubMed ID: 10051603
[TBL] [Abstract][Full Text] [Related]
35. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
36. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
37. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines.
Sharrard RM; Maitland NJ
Cell Signal; 2007 Jan; 19(1):129-38. PubMed ID: 16842970
[TBL] [Abstract][Full Text] [Related]
38. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.
Miletic AV; Anzelon-Mills AN; Mills DM; Omori SA; Pedersen IM; Shin DM; Ravetch JV; Bolland S; Morse HC; Rickert RC
J Exp Med; 2010 Oct; 207(11):2407-20. PubMed ID: 20956547
[TBL] [Abstract][Full Text] [Related]
39. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
Li D; Yang J; Ma H; Sun C; Feng R
J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
[TBL] [Abstract][Full Text] [Related]
40. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
